PCG Digital

Recent News

  • BIONIK Laboratories: Strong Sales Pipeline Delivering Hope to Stroke Survivors

    New York, New York--(Newsfile Corp. - May 25, 2022) - PCG Digital - Stroke is an enormous public health issue that can strike anyone at any time, regardless of age or health status. Worldwide, stroke is the second leading cause of death and a leading cause of serious long-term disability. According to the American Heart Association, each year stroke affects 800,000 individuals. More than two thirds of stroke survivors receive rehabilitation services after hospitalization.

    2022-05-25 10:45 AM EDT
  • Quoin Pharmaceuticals: On Track to Deliver the First FDA-Approved Treatment for Netherton Syndrome

    New York, New York--(Newsfile Corp. - May 17, 2022) - PCG Digital -- People with rare diseases face severe limitations, debilitating discomfort, and a very uncertain future. Children are especially vulnerable: 3 out of 10 children born with a rare disease do not live to see their 5th birthday. Rare diseases can be challenging to diagnose, but even once a diagnosis is reached, effective treatment options can be even more elusive.

    2022-05-17 8:30 AM EDT
  • Snacks Sabotaging Your Sleep? Nightfood Establishes Nighttime Snacking Category

    New York, New York--(Newsfile Corp. - May 11, 2022) - PCG Digital -- Anyone who has spent a night tossing and turning after eating the wrong thing before bed will tell you: What you eat before bed matters. Nighttime snacking company, Nightfood Holdings, Inc., (OTCQB: NGTF) is not only defining the problem of snacking between dinner and bedtime - which sees Americans spending $50 billion each year on evening snacks - but developing sleep-friendly solutions.The company's sleep-friendly snacking options...

    2022-05-11 12:09 PM EDT
  • Investing in 60 Seconds: Asensus Surgical

    New York, New York--(Newsfile Corp. - April 20, 2022) - PCG Digital -- Surgery can be unpredictable, and a staggering one in five patients undergoing surgery has one, or even multiple, preventable surgical complications.Asensus Surgical (NYSE American: ASXC) is setting a new standard for robotic, laparoscopic surgery with its technology platform, Senhance®, which enhances the work of surgeons using state-of-the-art robotics, augmented intelligence (AI) and machine learning (ML). The Senhance system provides surgeons with real-time clinical intelligence, allowing them to...

    2022-04-20 8:30 AM EDT
  • Quoin Pharmaceuticals Targeting Regulatory Approvals for Lead Candidate for Netherton Syndrome in 2024

    New York, New York--(Newsfile Corp. - March 24, 2022) - PCG Digital -- Netherton Syndrome (NS) is a rare and devastating skin disease that is estimated to affect between 2,000 and 4,000 people in the United States, and a similar number in Europe. It has no cure, and current treatment primarily involves the use of over-the-counter moisturizers which provide only minor symptomatic relief.Quoin Pharmaceuticals' (NASDAQ: QNRX) investigational product for NS, QRX003, may become the first approved treatment available to patients....

    2022-03-24 8:30 AM EDT
  • Changing Lives, Delivering Value: Quoin Pharmaceuticals is Making the Balancing Act Look Easy

    New York, New York--(Newsfile Corp. - February 8, 2022) - PCG Digital - Emerging specialty pharma company, Quoin Pharmaceuticals (NASDAQ: QNRX), coined the phrase 'Rare diseases are only rare if you don't live with one' to emphasize its own mission: to deliver unique solutions to help treat rare disorders that have no approved treatments or cures.

    2022-02-08 8:30 AM EST
  • Asensus Surgical: Reimagining the Future of Surgery

    New York, New York--(Newsfile Corp. - January 26, 2022) - -- PCG Digital-- Asensus Surgical, Inc. (NYSE American: ASXC) is leading the digital surgical market with a new concept known as Performance-Guided Surgery™. Asensus SurgicalTo view an enhanced version of this graphic, please visit:

    2022-01-26 1:10 PM EST
  • Soligenix Corporate Update Includes NDA Plans for HyBryte(TM)

    New York, New York--(Newsfile Corp. - January 12, 2022) - PCG Digital -- Soligenix, Inc. (NASDAQ: SNGX), a US-based late-stage biopharmaceutical company, issued a corporate update this week with good news for their shareholders. Despite supply-chain delays in receiving the active pharmaceutical ingredient for SGX301, aka HyBryte™, the company is still on track to file a new drug application with the FDA in the latter half of 2022. HyBryte™ is an early-stage treatment for cutaneous T-cell lymphoma (CTCL), a condition...

    2022-01-12 12:00 PM EST